Skip to main content
SpringerLink
Log in

Adjuvant chemotherapy in colon carcinoma stages II and III

  • Short Review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Adjuvant chemotherapy significantly improves disease-free survival and overall survival in colon cancer. Ongoing clinical trials are evaluating the addition of targeted therapies to standard regimen and the influence of gene expression signature as prognostic and predictive markers for the use of adjuvant chemotherapy. This review will summarize adjuvant therapeutic approaches in stages III and II colon cancer as well as therapeutic options in elderly patients and future developments in the adjuvant setting of colon cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Mathers C, Boschi-Pinto C. Global burden of cancer in the year 2000: version 1 estimates. World Health Organization, Geneva, 2003

  • O'Connell, Maggard MA, Ko CY, et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Nat Cancer Inst, 961420–961425, 2004

  • Moertel CG, Fleming TR, Macdonald JS, et al. Levamisol and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med, 322: 352–358, 1990

    Article  PubMed  CAS  Google Scholar 

  • Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of flurouracil plus levamisole as adjuvant therapy for stage II/Dukes'B2 colon cancer. J Clin Oncol, 13: 2936–2943, 1995

    PubMed  CAS  Google Scholar 

  • Porschen R, Bermann A, Löffler T, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol, 19: 1787–1794, 2001

    PubMed  CAS  Google Scholar 

  • Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol, 17: 3553–3559, 1999

    PubMed  CAS  Google Scholar 

  • O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295–300, 1998

    PubMed  Google Scholar 

  • Haller D, Catalano P, Macdonald J, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancers: Five-year final report of INT-0089. Proc Am Soc Clin Oncol, 17: 982, 1998

    Google Scholar 

  • Köhne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluoruracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol, 21: 3721–3728, 2003

    Article  PubMed  Google Scholar 

  • Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med, 352: 2696–2704, 2005

    Article  PubMed  CAS  Google Scholar 

  • Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and Tegafur plus leucovorin compared with intravenous flourouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol, 24: 2059–2064, 2006

    Article  PubMed  CAS  Google Scholar 

  • Popov I, Carrato A, Sobrero A, et al. Ralitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer, 44: 2204–2211, 2008

    Article  PubMed  CAS  Google Scholar 

  • André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the adjuvant treatment of colon cancer (MOSAIC). N Engl J Med, 350: 2343–2351, 2004

    Article  PubMed  Google Scholar 

  • Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol, 25: 2198–2204, 2007

    Article  PubMed  CAS  Google Scholar 

  • Haller DG, Tabernero J, Maroun J, et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin versus bolus 5-FU/LV for stage III colon cancer. Eur J Cancer Suppl, 7: 4, 2009

    Article  Google Scholar 

  • Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol, 23: 246 (Abstract 3500), 2004

    Google Scholar 

  • Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol, 27: 3117–3125, 2009

    Article  PubMed  CAS  Google Scholar 

  • Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + Irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol, 20: 674–680, 2009

    Article  PubMed  CAS  Google Scholar 

  • Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol, 22: 1797–1806, 2004

    Article  PubMed  CAS  Google Scholar 

  • Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370: 2020–2029, 2007

    Article  PubMed  Google Scholar 

  • Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol, 25: 4569–4574, 2007

    Article  PubMed  Google Scholar 

  • Benson AB, Schrag D, Somerfiled MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 22: 3408–3419, 2004

    Article  PubMed  Google Scholar 

  • Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med, 345: 1091–1097, 2001

    Article  PubMed  CAS  Google Scholar 

  • McCleary J, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol, 27: 15 (Abstract 4010), 2009

    Article  Google Scholar 

  • Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV in patients with metastatic colorectal cancer. J Clin Oncol, 21: 60–65, 2003

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, flurouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335–2342, 2004

    Article  PubMed  CAS  Google Scholar 

  • Saltz L, Diaz-Rubio E, Scheithauer W, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26: 2013–2019, 2008

    Article  PubMed  CAS  Google Scholar 

  • Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360: 1408–1417, 2009

    Article  PubMed  CAS  Google Scholar 

  • Bokemeyer C, Bondarenko I, Hartmann JT, et al. Overall survival of patients with KRAS wild-type tumors treated with FOLFOX4 + Cetuximab as 1st-line treatment for metastatic colorectal cancer: The Opus study. ECCO-ESMO, Abstract No 6.079, 2009

  • Douillard JY, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol, 28: 4697–4705, 2010

    Article  PubMed  CAS  Google Scholar 

  • Peeters M, et al. Randozmized phase III study of Panitumumab with fluorouracil, leucovorin and irinotectan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 28: 4706: 4713, 2010

    Article  PubMed  CAS  Google Scholar 

  • Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol, 29: 11–16, 2011

    Article  PubMed  CAS  Google Scholar 

  • De Gramont A, Van Cutsem E, Tabernero J, et al. AVANT: Results form a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX-4 versus FOLFOX-4 alone as adjuvant treatment for colon cancer. ASCO GI 2011, Abstract 362

  • Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG intergroup phase III trial N0147. J Clin Oncol, 28: 262 (Abstract CRA3507), 2010

    Article  Google Scholar 

  • Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol, 28: 3219–3226, 2010

    Article  PubMed  CAS  Google Scholar 

  • Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol, 66: 659–667, 2010

    Article  PubMed  CAS  Google Scholar 

  • Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol, 27: 1814–1821, 2009

    Article  PubMed  CAS  Google Scholar 

  • Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol, 29: 17–24, 2011

    Article  PubMed  Google Scholar 

  • Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol, 28: 466–474, 2010

    Article  PubMed  CAS  Google Scholar 

  • Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol, 24: 3527–3534, 2006

    Article  PubMed  Google Scholar 

  • Meyerhardt JA, Heseltine D, Niedwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol, 24: 3535–3541, 2006

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria

    G. Resch & J. Thaler

Authors
  1. G. Resch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Thaler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Resch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Resch, G., Thaler, J. Adjuvant chemotherapy in colon carcinoma stages II and III. memo 4, 86–89 (2011). https://doi.org/10.1007/s12254-011-0253-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-011-0253-8

Keywords

Search

Navigation